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Abstract
Gestational diabetes mellitus is a condition similar to type 2 diabetes mellitus (T2DM) in that patients are unable to compensate for the degree
of insulin resistance, and both conditions are often treated with metformin. The comparative pharmacodynamic response to metformin in these 2
populations has not been studied.This study characterized insulin sensitivity,β-cell responsivity, and disposition index following a mixed-meal tolerance
test utilizing a minimal model of glucose, insulin, and C-peptide kinetics before and during treatment with metformin. The study included women with
gestational diabetes mellitus (n = 34),T2DM (n = 14), and healthy pregnant women (n = 30). Before treatment, the gestational diabetes mellitus group
had significantly higher baseline (45%), dynamic (68%), static (71%), and total β-cell responsivity (71%) than the T2DM group. Metformin significantly
increased insulin sensitivity (51%) as well as disposition index (97%) and decreased mixed-meal tolerance test peak glucose concentrations (8%) in
women with gestational diabetes mellitus after adjustment for gestational age–dependent effects; however, in women with T2DM metformin only
significantly affected peak glucose concentrations (22%) and had no significant effect on any other parameters. Metformin had a greater effect on
the change in disposition index ( disposition index) in women with gestational diabetes mellitus than in those with T2DM (P = .01). In conclusion,
response to metformin in women with gestational diabetes mellitus is significantly different from that in women with T2DM,which is likely related to
the differences in disease severity.
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Gestational diabetes mellitus is a common complica-
tion during pregnancy and is associated with significant
adverse effects for the mother, fetus, and neonate.1–4
The underlying abnormalities and risk factors are
similar in women with gestational diabetes mellitus and
those with type 2 diabetes mellitus (T2DM), although,
in general, disease severity is greater with T2DM.5,6 In
both gestational diabetes mellitus and T2DM, patients
have marked insulin resistance and an inability to com-
pensate for the degree of insulin resistance. Metformin
is a drug that lowers glucose concentrations primarily
by decreasing insulin resistance through increasing
peripheral glucose uptake and utilization. Metformin
also decreases intestinal glucose absorption and hepatic
glucose production. Metformin is commonly used in
the treatment of women with T2DM and in women
with gestational diabetes mellitus.7 During pregnancy,
the majority of medications, including oral glucose-
lowering drugs such as metformin, are utilized in a sim-
ilar manner to their Food and Drug Administration–
approved indication in the nonpregnant population,
without comparative clinical pharmacological studies
being conducted during pregnancy to determine if this
approach is appropriate.5–7 Physiological, biochemical,
and hormonal changes during pregnancy are known to
alter the pharmacokinetics (PK) of drugs throughout
gestation.8 The renal clearance of metformin is
49% higher in midpregnancy and 29% higher in
late pregnancy compared with to the nonpregnant
state.9 In addition, we know that pregnancy is
associated with insulin resistance, hyperinsulinemia,
and changes in glucose handling.7 With differences
in metformin exposure, glucose handling, and disease
severity between gestational diabetes mellitus and
T2DM,7 it is likely that the pharmacodynamics
(PD) response to metformin will also differ between
pregnant women with gestational diabetes mellitus
and nonpregnant women with T2DM. No data exist
on how the PD of metformin in the treatment of
women with gestational diabetes mellitus compares
to that in women with T2DM. The objectives of this
study were to describe and provide preliminary data
comparing the PD response to metformin in women
with gestational diabetes mellitus and nonpregnant
women with T2DM. Mathematical modeling of
glucose, insulin, and C-peptide dynamics following a
mixed-meal tolerance test was used to estimate insulin
sensitivity, β-cell responsivity, and disposition index in
pregnant women with gestational diabetes mellitus and
nonpregnant women with T2DM.5,10 Insulin sensitivity
and β-cell responsivity are hyperbolically related and
informative in understanding the underlying pathology
of gestational diabetes mellitus and T2DM as well as
understanding metformin’s pharmacology.10,11
Methods
Subjects
The study was approved by the institutional review
boards at the University of Washington, Madigan
Army Medical Center, University of Texas Medical
Branch in Galveston, University of Pittsburgh, Indiana
University, University of Utah Health Care, University
of Alabama at Birmingham, and RTI International
and was conducted in accordance with their guide-
lines. All subjects gave written, informed consent. This
was a multicenter, prospective, phase 1/2 longitudinal
PD study (clinicaltrials.gov identifier NCT01329016).
There were 3 groups of women recruited for this
study: pregnant women with a diagnosis of gestational
diabetes mellitus (n = 34), gestational age-matched
healthy pregnant women (n = 30), and nonpregnant
women with a new diagnosis of T2DM (n = 14). Only
women who completed the study and adhered to the
protocol were included in the results. Subjects were
determined to be nonadherent based on unacceptable
study pill counts (any doses missed or time of dosage
>1 hour different from expected time of dosing in the
3 days before study day 2), physician clinical impres-
sion, or subject’s admittance to not having following
study protocol.
Entry Criteria
Gestational diabetes mellitus entry criteria included
pregnant women before 32 weeks of gestation, single-
ton pregnancy, 18-45 years of age, failed diet ther-
apy, and required drug treatment. Gestational diabetes
mellitus diagnosis was made in 1 of 3 ways based on
serum or plasma glucose concentrations: (1) 3-hour
oral glucose tolerance test (100 g glucose orally with
2 or more values meeting or exceeding targets: fasting
glucose 95 mg/dL, 1 hour 180 mg/dL, 2 hours
155 mg/dL, and 3 hours 140 mg/dL), (2) 2-
hour oral glucose tolerance test (75 g glucose orally
with 1 or more values meeting or exceeding targets,
fasting glucose 92 mg/dL, 1 hour glucose 180
mg/dL, 2 hours glucose >153 mg/dL), or (3) 1-
hour oral glucose tolerance test (50 g glucose orally
with 1 hour glucose 185 mg/dL). The women with
gestational diabetes mellitus who received metformin
for treatment in this study came from another study
in which women with gestational diabetes mellitus
were randomized to 1 of 3 treatment arms (met-
formin, glyburide, or combination therapy with met-
formin and glyburide).10 Only the women assigned to
metformin monotherapy were included in this study.
T2DM entry criteria included nonpregnant women, 18-
45 years of age, new diagnosis of T2DM, hemoglobin
A1C >7%, and expected to receive metformin treat-
ment. Exclusion criteria for women with gestational
diabetes mellitus or T2DM included medications
expected to interact with metformin, medications ex-
pected to alter blood glucose concentrations, serum
creatinine >1.2 mg/dL, hematocrit <28%, allergy to
metformin, significant liver disease (diagnosis of liver
disease other than Gilbert syndrome), congestive heart
failure or history of myocardial infarction, moderate
to severe pulmonary disease (any pulmonary disease
requiring drug treatment other than mild exercise-
induced asthma requiring only intermittent phar-
macologic treatment for which the patient was not
currently receiving drug therapy), and adrenal or pi-
tuitary insufficiency. Healthy pregnant women’s entry
criteria included singleton pregnancy, 18-45 years of
age, 20-32 weeks of gestation, and a normal 1-hour or
2-hour oral glucose tolerance test. Exclusion criteria
for healthy pregnant women included hematocrit<28%
or known kidney, liver, heart, pulmonary, adrenal, or
pituitary disease as well as those receiving glucose-
lowering agents or corticosteroids.
Treatment
All subjects with gestational diabetes mellitus and
T2DM in this studywere treated withmetformin. Titra-
tion schematic for subjects with gestational diabetes
mellitus can be found in the previously published parent
study.10 In brief, metformin was started at 500 mg
orally twice daily and titrated to clinical control or
treatment failure. For women with gestational diabetes
mellitus, blood glucose concentrations were considered
controlled when 75% of fasting glucose concentra-
tions were 95 mg/dL and 75% of either 1-hour
postprandial glucose concentrations were <140 mg/dL
or 2-hour postprandial glucose concentrations were
<120 mg/dL. For women with T2DM, clinical control
was based on hemoglobin A1C (target A1C < 7%).
Provider discretion was allowed for dosage titration.
Dosage initiation and titration for women with T2DM
was entirely based on clinical need without regard to
the study. Metformin was provided to all subjects with
gestational diabetes mellitus and T2DM for the 3 days
preceding study day 2. Metformin was at steady state
(consistent dosage for a minimum of 1 week) before
evaluation of insulin sensitivity, β-cell responsivity, and
disposition index during therapy (study day 2). Healthy
pregnant subjects did not receive metformin.
Mixed-Meal Tolerance Test
Insulin sensitivity, β-cell responsivity, and disposition
index were estimated before (study day 1) and during
treatment (study day 2) utilizing amixed-meal tolerance
test, which involved consuming 1 can of Boost Plus
energy drink and 2 slices of whole wheat toast with
two teaspoons of margarine and consumed within
10 minutes. Serial blood samples were collected before
the mixed-meal tolerance test (time = 0) and 10, 20, 30,
60, 90, 120, 150, 180, 210, and 240minutes following the
initiation of the mixed-meal tolerance test to measure
serum glucose, insulin, and C-peptide concentrations.
Plasma samples were collected at times 0, 0.5, 1, 1.5, 2,
2.5, 3, 4, 5, 6, 8, 10, and 12 hours postdose, truncated
to the dosing interval, for measurement of metformin
concentrations. Blood glucose concentrations were also
measured at each time point in real time on each
study day for safety assessment. Study day 2 took
place once subjects achieved clinical control or before
switching therapy if they failed to achieve glycemic
control. On study day 2, the metformin morning dose
was given at time 0 (pre–mixed-meal tolerance test),
and blood sampling was conducted as during study
day 1. Glucose concentrations were measured using
a glucose oxidase/peroxidase assay.12 Insulin and C-
peptide concentrations were measured using previously
described radioimmunoassays.13,14
Mixed-Meal Tolerance Test Parameter Estimation
Insulin sensitivity; total, baseline, static, and dynamic
β-cell responsivity; and disposition index were es-
timated pretreatment and during metformin treat-
ment as previously described utilizing SAAM II
software (version 2.3, The Epsilon Group, Char-
lottesville, Virginia).5,10,15–20 In brief, insulin sensitivity,
defined as the ability of insulin to normalize glucose
concentrations by stimulating uptake of glucose and
suppressing its production, was estimated from glucose
and insulin concentrations using the minimal model of
glucose kinetics after the mixed- meal tolerance test.
Model structure and equations have been previously
published.15 β-cell responsivity during the mixed-meal
tolerance test was estimated from serum glucose and
C-peptide concentrations using the minimal model of
C-peptide kinetics. C-peptide was used in the model
to provide an accurate reconstruction of prehepatic
secretion. The equations for the model have been pub-
lished previously.19,20 Disposition index was calculated
for each individual subject as the product of insulin sen-
sitivity and total β-cell responsivity. It allows evaluation
of an individual’s glucose tolerance as a function of
both insulin sensitivity and β-cell function.10,15–20
The area under the concentration-time curves for
glucose, C-peptide, insulin, and metformin were cal-
culated using the trapezoidal rule. PD response to
metformin was based on an expected increase in in-
sulin sensitivity. Gestational age-matched healthy preg-
nant subjects were studied to estimate gestational age-
dependent changes in insulin sensitivity and β-cell
responsivity between study day 1 and study day 2. Since
the PDparameters are gestational age dependent and to
evaluate specifically the drug effect, we subtracted out
the gestational age effect from study day 2 in the women
with gestational diabetes mellitus. The correction for
gestational age-dependent effect was accomplished by
subtracting the average difference between study day
2 and study day 1 in the healthy pregnant subjects
from individual study day 2 parameters for the subjects
with gestational diabetes mellitus.10 Changes in PD
parameters () were determined by subtracting PD
parameters estimated pretreatment on study day 1 from
those estimated posttreatment on study day 2 corrected
for gestational age-dependent effects in women with
gestational diabetes mellitus.
Plasma Metformin Concentration Analysis
Serial blood samples were collected predose and then
0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, and 12 hours postdose,
truncated to the dosing interval, for measurement of
metformin plasma concentrations utilizing a validated
liquid chromatography–tandem mass spectrometric as-
say as previously described.21 Metformin area under
the concentration-time curve over 1 dosing interval was
determined utilizing a trapezoidal rule.
Statistical Analyses
Statistical comparisons of PD parameters between
study day 1 and study day 2 utilized a paired Student
t test. The mean percentage difference from study day
1 to study day 2 was calculated as the mean change
divided by the mean value on study day 1. Statistical
comparisons between gestational diabetes mellitus and
T2DM utilized an unpaired Student t test. P-values
were not adjusted for multiple comparisons. Statistical
results are reported where appropriate as mean ± SD
(95%CI). All statistical analyses were done using R-
based programs,22 and graphs were generated in R
using the package ggplot2.23
Power Analysis
This study is 1 component of a larger study evaluating
the effects of oral glucose-lowering agents in the treat-
ment of women with gestational diabetes mellitus and
T2DM. Thirty subjects were anticipated to be needed
to detect a 50% change in insulin sensitivity.10
Results
Demographics
Demographics for adherent subjects with gestational
diabetes mellitus, those with T2DM, and healthy preg-
nant subjects who completed the study are reported
in Table 1. Demographics for all gestational diabetes
mellitus and T2DM subjects can be found in Supple-
mentary Table S1.No significant differences were found
in race or ethnicity between study arms (P  1). Age,
weight, and body mass index were not significantly dif-
ferent between gestational diabetes mellitus and T2DM
groups. Similar race and ethnicity distributions were
Table 1. Demographics, Metformin Dosing, and Area Under the
Concentration-Time Curve for Subjects With Gestational Diabetes
Mellitus, Nonpregnant Subjects With Type 2 Diabetes Mellitus, and
Healthy Pregnant Subjects
GDM T2DM HP
n 25 12 28
Age SD1 (y) 31 ± 5
(22 to 39)
33 ± 7
(23 to 45)
25 ± 5
(18 to 38)
Height SD1 (cm) 163 ± 6
(155 to 179)
160 ± 8
(147 to 175)
162 ± 8
(147 to 178)
Body weight SD1 (kg) 90 ± 20
(70 to 100)
100 ± 30
(60 to 100)
80 ± 10
(50 to 109)
BMI prepregnancy
(kg/m2)
31 ± 6
(21 to 43)
36 ± 7
(24 to 46)
27 ± 5
(20 to 40)
GA, SD1 (wk) 31 ± 2
(20 to 33)
NA 30 ± 1
28 to 33)
GA, SD2 (wk) 35 ± 1
(32 to 38)
NA 36 ± 1
(34 to 38)
Metformin dose SD2
(mg/day)
1400 ± 500
(1000 to 2000)
800 ± 200
(500 to 1000)
NA
Metformin AUC
(µg•h/mL)
11 ± 4 12 ± 3 NA
White 80% 75% 82%
Black 16% 25% 18%
Asian 4% 0% 0%
Hispanic/Latina 36% 67% 32%
Baseline C-peptide
AUC (pmol•h/L)
12 000 ± 4000 8000 ± 4000 9000 ± 3000
Baseline glucose AUC
(mg•h/L)
500 ± 70 1000 ± 400 380 ± 40
Baseline insulin AUC
(µU•h/mL)
300 ± 100 200 ± 200 190 ± 80
AUC indicates area under the concentration-time curve; BMI, body mass
index; GA, gestational age; GDM, gestational diabetes mellitus; T2DM, type
2 diabetes mellitus;HP, healthy pregnant subjects; SD1, study day 1; SD2, study
day 2.
Results reported as mean ± SD.
reported for healthy pregnant subjects who completed
the study. There was an average of 5 weeks between
study days for the subjects with gestational diabetes
mellitus and 15 weeks for the subjects with T2DM.
Gestational Age Correction
In the subjects with gestational diabetes mellitus, the
correction for gestational age–dependent changes be-
tween study days 1 and 2 can be found in Supplemen-
tary Table S2.
PD Parameters Within Group Comparisons
In the women with gestational diabetes mellitus, met-
formin increased insulin sensitivity 51% (P = .005),
total β-cell responsivity 26% (P = .04), static β-cell
responsivity 29% (P = .04), and disposition index
97% (P = .003) compared with baseline (ie, study day
2 versus study day 1), and decreased baseline β-cell
responsivity 24% (P= .004), and mixed-meal tolerance
test peak glucose concentration 8% (P = .006) but had
no significant effect on dynamic β-cell responsivity. In
Table 2. Pharmacodynamic Parameters Following a Mixed-Meal Tolerance Test on Study Day 1 (Pretreatment) and Study Day 2 (With Metformin
Treatment) in Nonpregnant Control Subjects With Type 2 Diabetes Mellitus and Women With Gestational Diabetes Mellitus, Corrected for
Gestational-Age–Dependent Changes
GDM (n = 25) T2DM (n = 12)
Parameter SD1 SD2  SD1 SD2 
SI (10-4 min-1 µU-1 mL) 3 ± 2 4 ± 2 2 ± 2
(0.5 to 3)
(P = .005)*
5 ± 8 6 ± 5 1 ± 5
(–2 to 4)
(P = .4)
total (10-9 min-1) 100 ± 50 130 ± 70 30 ± 60
(1 to 50)
(P = .04)*
30 ± 30 40 ± 30 10 ± 20
(–0.4 to 30)
(P = .06)
static (10-9 min-1) 90 ± 40 120 ± 70 30 ± 60
(1 to 50)
(P = .04)*
30 ± 30 40 ± 30 10 ± 20
(–0.6 to 30)
(P = .06)
dynamic (10-9) 2000 ± 1000 2000 ± 1000 100 ± 1000
(–300 to 600)
(P = .5)
600 ± 900 600 ± 700 50 ± 700
(–400 to 500)
(P = .8)
baseline
(10-9 min-1) 11 ± 5 9 ± 6 –3 ± 4
(–4 to –0.9)
(P = .004)*
6 ± 4 7 ± 4 1 ± 2
(–0.3 to 2)
(P = .1)
DI (10-13 min-2 µU-1 mL) 300 ± 300 600 ± 400 300 ± 500
(100 to 500)
(P = .003)*
200 ± 300 200 ± 200 40 ± 100
(–50 to 100)
(P = .4)
MMTT peak glucose (mg/dL) 150 ± 20 140 ± 20 –10 ± 20
(–20 to –4)
(P = .006)*
280 ± 80 220 ± 80 –60 ± 90
(–100 to –4)
(P = .04)*
DI indicates disposition index; GDM, gestational diabetes mellitus group;MMTT,mixed-meal tolerance test; SD1/SD2, study day 1/2; SI, insulin sensitivity; T2DM,
type 2 diabetes mellitus group;, average change between SD1 and SD2;, β-cell responsivity.
Results reported as mean ± SD (95%CI).
*Statistically different (P .05) comparing SD2 to SD1.
the subjects with T2DM there was a 22% decrease in
peak glucose concentration (P = .04, Table 2) with
metformin, but none of the estimated PD parameters
were significantly altered by metformin in this group.
Gestational Diabetes Mellitus Versus T2DM Disease
Severity
Table 3 provides mean difference data for mixed-meal
tolerance test baseline parameters between pregnant
women with gestational diabetes mellitus and nonpreg-
nant women with T2DM. Mean β-cell responsivity
parameters were higher in the women with gestational
diabetes mellitus at baseline than in the nonpregnant
women with T2DM. Specifically, baseline β-cell re-
sponsivity was an average of 45% higher (P = .002),
dynamic β-cell responsivity 68% higher (P = .0009),
static β-cell responsivity 71% higher (P = .000007),
and total β-cell responsivity 71% higher (P = .000003)
in the women with gestational diabetes mellitus as
compared with the nonpregnant women with T2DM.
In addition, mean mixed-meal tolerance test peak
glucose concentrations were on average 48% lower
(P= .0002) in women with gestational diabetes mellitus
than in women with T2DM. The pretreatment mean
disposition index curves for subjects with T2DM and
gestational diabetes mellitus are depicted in Figure 1.
Table 3. Disease Severity: Mean Difference in Pretreatment, Baseline
Mixed-Meal Tolerance Test Parameters for Women With Gestational
Diabetes Mellitus and Nonpregnant Women With Type 2 Diabetes
Mellitus
Parameter Mean Difference P Value
SI (10-4 min-1 µU-1 mL) −2 .4
(−7 to 3)
total (10-9 min-1) 73 .000003
(47 to 99)
static (10-9 min-1) 63 .000007
(39 to 87)
dynamic (10-9) 1302 .0009
(597 to 2007)
baseline (10-9 min-1) 5 .002
(2 to 8)
DI (10-13 min-2 µU-1 mL) 157 .1
(−52 to 366)
MMTT peak glucose (mg/dL) −136 .0002
(−190 to −82)
DI indicates disposition index; MMTT, mixed-meal tolerance test., average
change between SD1 and SD2;, β-cell responsivity.
Results reported as mean (95%CI). Refer to Table 2 for baseline actual
parameter values.
Although the mean disposition index curve for subjects
with T2DM relative to those with gestational diabetes
mellitus on study day 1 appears shifted down and to
the left, because of intersubject variability, there were
Figure 1. Pharmacodynamic effects of metformin in women with gestational diabetes mellitus (GDM) and type 2 diabetes mellitus (T2DM). Mean
disposition index for all adherent subjects who completed the study in the GDM metformin (MET) arm at baseline (solid gray line) and on study day 2
(dashed gray line) as well as for subjects with T2DM at baseline (solid black line) and on study day 2 (dashed black line). The vectors depict the mean
pharmacodynamic effect of metformin in subjects with GDM (gray arrow) and subjects with T2DM (black arrow). Solid dots represent mean baseline
disposition index (study day 1), and open circles represent study day 2 mean disposition index (GDM corrected for mean gestational age-dependent
change).total indicates total beta-cell responsivity.
no significant differences in disposition index or insulin
sensitivity between groups at baseline.
Metformin Dose per Day
Average metformin dose per day on study day 2 for
subjects with gestational diabetes mellitus and T2DM
can be seen in Table 1. The mean metformin dose per
day in the women with gestational diabetes mellitus was
higher than that for the women with T2DM (difference
607 [95%CI 369 to 844] mg, P < .001). However, due
to differences in PK during pregnancy as compared
with the nonpregnant state,meanmetformin area under
the concentration-time curve was 14% smaller in the
women with gestational diabetes mellitus as compared
with the women with T2DM. This difference is not
statistically significant (gestational diabetes mellitus
11 ± 4 µg•h/mL versus T2DM 12 ± 3 µg•h/mL,
P = .2).
PD Effect of Metformin in Subjects With Gestational
Diabetes Mellitus Versus Nonpregnant Subjects With
T2DM
Figure 1 depicts the average disposition index curves for
each group on study day 1 and study day 2. Figure 1
also depicts the mean metformin pharmacologic PD
response vectors for subjects with gestational diabetes
mellitus and nonpregnant subjects with T2DM starting
at their pretreatment average disposition index on study
day 1 and extending to the concomitant treatment
average disposition index on study day 2. With met-
formin treatment the disposition index curve shifted up
and to the right in women with T2DM but reached
the pretreatment disposition index curve only for the
women with gestational diabetes mellitus. When the
change from study day 1 to study day 2 with metformin
was compared (Table 4), the mean  disposition index
was greater for the women with gestational diabetes
mellitus (300 ± 500 10−13 min−2 µU−1 mL) than for
the women with T2DM (40 ± 100 10−13 min−2 µU−1
mL, P = .01). There was no significant difference in
 insulin sensitivity (P = .9) or β-cell responsivity
(P= .4) with metformin in women with gestational dia-
betes mellitus versus nonpregnant women with T2DM.
Mean peak glucose concentrations decreased with met-
formin treatment in both T2DM (mean difference
60 ± 90 mg/dL, P= .04) and gestational diabetes melli-
tus (mean difference 10 ± 20 mg/dL, P = .006) groups.
Eighty-four percent of the subjects with gestational
diabetes mellitus and 83% of the subjects with T2DM
had some pharmacologic response to metformin (ie,
increase in insulin sensitivity).
Mean differences in PD parameters following the
mixed-meal tolerance test on study day 2 while on
treatment with metformin in subjects with gestational
Table 4. Mean Difference in Mixed-Meal Tolerance Test Parameters
During TreatmentWith Metformin (Study Day 2 and Change From Study
Day 1 to Study Day 2) for Women With Gestational Diabetes Mellitus
and Nonpregnant Women With Type 2 Diabetes Mellitus
Parameter
Mean
Difference on
SD2 Between
Study Arms
P Value
Comparing
Mean Value
on SD2
Between
Study Arms
P Value
Comparing
Mean
Change
From SD1
to SD2
Between
Study Arms
SI (10-4 min-1 µU-1
mL)
–1.6 .3 .9
(–5.2 to 1.86)
total (10-9 min-1) 86 .00001 .4
(51 to 121)
static (10-9 min-1) 76 .00005 .4
(43 to 109)
dynamic (10-9 min-1) 1400 .00006 .7
(779 to 2020)
baseline (10-9 min-1) 1.4 .4 .001
(–2.3 to 5.1)
DI (10-13 min-2
µU-1 mL)
422 .0001 .01
(227 to 617)
Peak glucose
(mg/dL)
−85 .002 .08
(−133 to
−37)
DI indicates disposition index; GDM, gestational diabetes mellitus; SD1/SD2,
study day 1/2; SI, insulin sensitivity; total , total β-cell responsivity; static,
static β-cell responsivity; dynamic, dynamic β-cell r; baseline, baseline β-cell
responsivity.
Results reported as mean ± SD. The values for women with GDM were
adjusted to account for normal gestational-age–dependent. Refer to Table 2
for actual parameter values.
diabetes mellitus and subjects with newly diagnosed
T2DMare shown in Table 4.While receivingmetformin
treatment, the average disposition index for women
with gestational diabetes mellitus was 3-fold higher
than the average disposition index for women with
T2DM (mean difference 421 × 10−13 min−2 µU−1 mL,
P= .0001). In addition, while on metformin treatment,
the average peak mixed-meal tolerance test glucose
concentration was 85 mg/dL lower in the women with
gestational diabetes mellitus than in those with T2DM
(P = .002).
Safety
The adverse effects associated with the mixed-meal
tolerance test were limited to occasional bruising from
phlebotomy. No hypoglycemia was noted during the
mixed-meal tolerance test with either group.
Discussion
For the most part, clinical trials for new drugs have
been conducted in nonpregnant individuals. Our under-
standing of the clinical pharmacology of medications
during pregnancy is growing,5,9,10,24 but most medi-
cation prescribing during pregnancy is based on data
collected from the nonpregnant population. Normal
pregnancy is associated with lower fasting and prepran-
dial glucose concentrations and much higher peak
insulin concentrations than are seen in the nonpregnant
population.7 This is likely due in part to the insulin
resistance that occurs during normal pregnancy.6 Met-
formin is approved by the Food and Drug Adminis-
tration for treatment of patients with T2DM. There
has been discussion in the literature as to whether
or not gestational diabetes mellitus and T2DM are
the same condition.25 Both conditions are associated
with insulin resistance and decreased pancreatic β-cell
compensation ability.6,26
Insulin sensitivity, β-cell responsivity, and
disposition index with glyburide have been reported for
patients with gestational diabetes mellitus and T2DM.5
With glyburide treatment, women with gestational
diabetes mellitus have greater total (ie, overall insulin
response) and static (ie, second-phase insulin response)
β-cell responsivity than women with T2DM.5 In
this study, before metformin treatment, women with
gestational diabetes mellitus demonstrated not only
better total and static β-cell responsivity, but also
dynamic (ie, first-phase insulin response) and baseline
(ie, basal, nonstimulated index of insulin secretion)
β-cell responsivity compared with those with T2DM.
This is consistent with more severe pancreatic β-cell
dysfunction in women with T2DM than in those with
gestational diabetes mellitus. However, overall dispo-
sition index at baseline for women with gestational
diabetes mellitus and nonpregnant women with T2DM
was not significantly different in either this study or
our previous work.6 With these underlying differences
in disease severity before treatment, it is reasonable
to question whether the clinical pharmacological
response to treatment will also differ during pregnancy.
Data are extremely limited on the PD effects of
medications during pregnancy, including metformin.
This study provides preliminary data comparing the
PD of metformin treatment in women with gestational
diabetesmellitus and nonpregnant womenwith T2DM.
Women with gestational diabetes mellitus have a
7-fold increased risk for developing T2DM later in
life than women without gestational diabetes mellitus
during pregnancy.27 This is not surprising given the
similar risk factors, such as obesity, as well as sim-
ilar pathology, including increased insulin resistance
and decreased ability to compensate for the degree
of insulin resistance in women with gestational dia-
betes mellitus and those with T2DM. Metformin is
the most commonly utilized treatment for patients
with T2DM. The difference in metformin response in
women with gestational diabetes mellitus as compared
with nonpregnant women with T2DM is complicated
by baseline differences in pregnancy status, which in-
creases insulin resistance, as well as disease state. That
being said, we report for the first time that a similar
percentage of women receiving metformin experienced
some positive effect on insulin sensitivity if they had
gestational diabetes mellitus (84%) or T2DM (83%).
Despite this similarity, the magnitude of response to
metformin differed between women with gestational
diabetes mellitus and those with T2DM for some PD
parameters. On average,metformin treatment inwomen
with gestational diabetes mellitus had a greater effect
on the change in disposition index than women with
T2DM (P= .01), but there was no significant difference
in the change in peak glucose concentrations between
women with gestational diabetes mellitus and T2DM
(P= .08). Of note, although average metformin dosage
was higher in the women with gestational diabetes
mellitus, due to the PK differences in pregnancy as
compared with the nonpregnant state,9 there was no
significant difference in metformin exposure as mea-
sured by area under the concentration-time curve com-
pared with the nonpregnant women with T2DM in this
study.
Metformin decreases insulin resistance through
decreased glycogenolysis, lipolysis, and activity of
hepatic glucose-6-phosphatase as well as increased
glycogen synthesis, insulin receptor tyrosine kinase
activity, and glucose transporter type 4 (GLUT4)
activity.28,29 Our data with metformin in the
treatment of women with gestational diabetes mellitus
demonstrate improvement in insulin sensitivity,
consistent with its primary mechanism of action.
Metformin can also increase insulin secretion through
increasing the release of glucagon-like-peptide-1 (GLP-
1).29 GLP-1 is known to improve β-cell activity, which
should translate into increased β-cell responsivity.30,31
Interestingly, in contrast to expectations for a drug
that has been reported to increase release of GLP-1,
metformin significantly decreased the baseline β-
cell responsivity in women with gestational diabetes
mellitus, which likely reflects the changes seen in insulin
sensitivity. Consistent with expectations, metformin
increased total β-cell responsivity by 26% and static
β-cell responsivity by 29%, although there was no
significant change in dynamic β-cell responsivity. Most
importantly, metformin improved the disposition
index, a measure of the overall metabolic state, by 97%,
shifting the disposition index curve up and to the right
in women with gestational diabetes mellitus. In contrast
to the results in women with gestational diabetes melli-
tus, the women with T2DM had no significant change
in any of the PD parameters with metformin. This is to
some extent a result of the smaller number of subjects
studied with T2DM, a limitation of this preliminary
work.
However, when our data in patients with T2DM
were compared with previously reported effects of
metformin in nonpregnant patients with T2DM, our
subjects with T2DM were similar but had less disease
severity based on mean insulin sensitivity (this study
5 × 10−4 min−1 µU−1 mL versus previous work 2.8-
2.1 × 10−4 min−1 µU−1 mL), total β-cell responsivity
(this study 30 × 10−9 min−1 versus previous work 6.4-
7.4 × 10−9 min−1), static β-cell responsivity (this study
30 × 10−9 min−1 versus previous work 12.2-15.5 ×
10−9 min−1), dynamic β-cell responsivity (this study
600× 10−9 min−1 versus previous work 418–480× 10−9
min−1), baseline β-cell responsivity (this study 6× 10−9
min−1 versus previous work 4.6-5.5 × 10−9 min−1), and
disposition index (this study 200 × 10−13 min−2 µU−1
mL versus previous work 17.4-20 × 10−13 min−2 µU−1
mL).32 Response to metformin was also similar in our
subjects with T2DM to that reported in the literature
based on insulin sensitivity (this study 1 × 10−4 min−1
µU−1 mL versus previous work 0.1-0.7 × 10−4 min−1
µU−1 mL), total β-cell responsivity (this study 10 ×
10−9 min−1 versus previouswork 1.2-2.4× 10−9 min−1),
static β-cell responsivity (this study 10 × 10−9 min−1
versus previous work 5.9-13 × 10−9 min−1), dynamic
β-cell responsivity (this study 50 × 10−9 min−1 versus
previous work 31-54 × 10−9 min−1), baseline β-cell
responsivity (this study 1 × 10−9 min−1 versus previous
work 0.5-1.3 × 10−9 min−1), and disposition index (this
study 40 × 10−13 min−2 µU−1 mL versus previous work
5.2-11.6 × 10−13 min−2 µU−1 mL).32
On study day 2 (during metformin treatment) in
a similar pattern to study day 1 (before metformin
treatment), women with gestational diabetes mellitus
had closer to normal (ie, significantly higher) β-cell
responsivity (total, dynamic, and static) than women
with T2DM. However, whereas there was a signif-
icant difference before treatment in baseline β-cell
responsivity, with metformin treatment this difference
was no longer observable. This appears to be driven
by the decrease in baseline β-cell responsivity with
metformin treatment in the women with gestational
diabetes mellitus and no change from baseline in β-cell
responsivity in the women with T2DM. In addition, the
overall metabolic states (ie, disposition index) were not
different between the 2 groups at baseline but became
markedly different with metformin treatment. Women
in the gestational diabetes mellitus group were much
better able to compensate for the degree of insulin
resistance than the women with T2DM. Because the
ability to compensate for the degree of insulin resistance
is key to maintaining glycemic control, this difference is
critically important and is an apt illustration of the need
not only for rigorous PK studies in pregnancy but also
for PD studies comparing response to the nonpregnant
population.
Limitations of Study
This study provides preliminary data on the PD of
metformin during pregnancy as compared with non-
pregnant patients with type 2 diabetes mellitus and
should be interpreted with care. A major limitation
of this study is the small sample size in the T2DM
study group. This group was intended to be larger
and equivalent in number to the gestational diabetes
mellitus study group, but due to slow enrollment in
this arm and the end of the funding cycle, the funding
agency closed the study for further enrollment.
Another limitation of this study is the multiple test-
ing performed without adjustment for multiple com-
parisons. This article focused on 2 arms of a larger
study, and it is unclear what should be considered
a “family” of tests for this report in analyzing and
interpreting a subset of those data. Further, adjusting
P values for comparisons and analyses not presented
herein would be confusing for the reader and chal-
lenging to explain. Therefore, we did not make any
adjustments for multiple testing but did make it clear
to the reader that this was the case.
Last, the use of the mixed-meal tolerance test
method to derive the PD parameters provides the
advantages that it is well tolerated by patients, easy
to administer, includes the effects of gastrointestinal
incretins, and correlates well with the gold standard
hyperglycemic clamp studies. However, it is limited
because it does require assumption making regarding
the rate of nutrient absorption and requires significant
mathematical modeling.
Conclusions
This study describes and compares the clinical phar-
macologic PD response to metformin in women with
gestational diabetes mellitus and nonpregnant women
with T2DM. The clinical pharmacological response to
metformin treatment is significantly different in preg-
nant women with gestational diabetes mellitus than in
nonpregnant women with T2DM, which likely reflects
differences in disease severity. With similar metformin
exposure, women with gestational diabetes mellitus
have a greater improvement in overall disposition index
with metformin treatment than nonpregnant women
with T2DM.
Acknowledgments
In memoriam we acknowledge the tremendous contribution
of David A. Flockhart, PhD, MD, to the Obstetric-fetal
Pharmacology Research Unit Network. We also thank
the research coordinators and nurses including Alisha
Bouge, Claudine Hernandez, Karen Hays, Ira Kantrowitz-
Gordon, Anna Lemchen, Heather Johnson, Holly West, Julie
Croxford, Dawn Fisher, Wenchen Zhao, Becky Cypher, and
Janie Klank for their hard work in completing this study.
This research was supported in part by the Eunice Kennedy
Shriver National Institute of Child Health and Human
Development grants U10HD063094, U10HD047892,
U10HD047905, U10HD047891, and U10HD057753, the
NIH National Center for Advancing Translational Science
through the Clinical and Translational Science Awards
Program grants ULITR000423, TLITR000422, and
ULITR001108, National Institute of General Medical
Sciences R01GM124264, and unrestricted research funds
from the University of Washington. The content of this
article is solely the responsibility of the authors and does
not necessarily represent the official views of the Eunice
Kennedy Shriver National Institute of Child Health and
HumanDevelopment or the National Institutes of Health. In
addition, the views expressed are those of the author(s) and
do not reflect the official policy or position of the US Army
Medical Department, Department of the Army, Department
of Defense, or the US Government. The investigators have
adhered to the policies for protection of human subjects as
prescribed in 45 CFR 46.
Author Contributions
D.L.S. was responsible for pharmacodynamic modeling and
writing/editing of this manuscript; L.M.S. carried out data
analysis and manuscript editing; X.M. and D.D.S. were
responsible for study design, pharmacodynamic modeling,
and manuscript editing; S.K.F.-N., S. Clark, S. Caritis, D.H.,
S.K.Q., L.S.H., A.T.T., T.M., and K.E.T. contributed to
study conduct and manuscript editing; M.A. performed
metformin sample analysis and manuscript editing; R.V.
contributed to glucose, insulin, and C-peptide analysis and
manuscript editing; Z.R. performed study protocol develop-
ment and manuscript editing; Z.B. carried out study design
and manuscript editing; T.R.E. was responsible for study
design, study conduct, and manuscript editing; L.M.B. con-
tributed to study protocol development and data compilation
and coordination; and M.F.H. was responsible for study
design, study conduct, data analysis, and manuscript writing
and editing.
Conflicts of Interest
D.L.S. declares that, at the time of the conduct and analysis
of the study, she had no conflict of interest. However, since
the completion of the study, D.L.S.’s affiliation has changed
to PRA Health Sciences. X.M. is an employee of Eli Lilly
and Company. All other authors declare that at the time of
the conduct and analysis of the study, they had no conflicts
of interest. A professional medical writing company was not
used for preparation of this manuscript.
Data Sharing
Readers should contact Dr Mary Hebert (mhebert@uw.edu)
for questions regarding data sharing.
References
1. Jovanovic L, Pettitt DJ. Gestational diabetes mellitus. JAMA.
2001;286:2516-2518.
2. PagliaMJ, Coustan DR. Gestational diabetes: evolving diagnos-
tic criteria. Curr Opin Obstet Gynecol. 2011;23:72-75.
3. HAPO Study Cooperative Research Group. The Hyperglycemia
and Adverse Pregnancy Outcome (HAPO) Study. Int J Gynaecol
Obstet. 2002;78:69-77.
4. American College of Obstetricians and Gynecologists Commit-
tee on Practice Bulletins—Obstetrics, ACOG Practice Bulletin.
Clinical management guidelines for obstetrician-gynecologists.
Number 30, September 2001 (replaces Practice Bulletin Number
180, July 2017). Gestational diabetes mellitus. Obstet Gynecol.
2018;131(2):e49-e64.
5. Hebert MF, Ma X, Naraharisetti SB, et al. Are we optimizing
gestational diabetes treatment with glyburide? The pharmaco-
logic basis for better clinical practice. Clin Pharmacol Ther.
2009;85:607-614.
6. Buchanan TA. Pancreatic B-cell defects in gestational diabetes:
implications for the pathogenesis and prevention of type 2
diabetes. J Clin Endocrinol Metab. 2001;86:989-993.
7. Phelps RL, Metzger BE, Freinkel N. Carbohydrate metabolism
in pregnancy. XVII. Diurnal profiles of plasma glucose, in-
sulin, free fatty acids, triglycerides, cholesterol and individual
amino acids in late normal pregnancy. Am J Obstet Gynecol.
1981;140(7):730-736.
8. Klieger C, Pollex E, Kazmin A, Koren, G. Hypoglycemics:
pharmacokinetic considerations during pregnancy. Ther Drug
Monit. 2009;31:533-541.
9. Eyal S, Easterlin TR, Carr D, et al. Pharmacokinetics of
metformin during pregnancy. Drug Metab Dispos. 2010;38:833-
840.
10. Shuster DL, Shireman LM, Ma X, et al. Pharmacodynamics
of glyburide, metformin and glyburide/metformin combination
therapy in the treatment of gestational diabetes mellitus. Clin
Pharmacol Ther. In press.
11. Bergman, R.N. Minimal model: perspective from 2005. Horm
Res. 2005;64:8-15.
12. Bandi ZL, Fuller JB, Bee DE, James GP. Extended clinical
trial and evaluation of glucose determination with the Eastman
Kodak Ektachem GLU/BUN Analyzer. Clin Chem. 1981;27:27-
34.
13. Haffner SM, Mykkanen L, Stern MP, Valdez RA, Heisserman
JA, Bowsher RR. Relationship of proinsulin and insulin to
cardiovascular risk factors in nondiabetic subjects. Diabetes.
1993;42:1297-1302.
14. Wiedmeyer HM, Polonsky KS, Myers GL, et al. Interna-
tional comparison of C-peptide measurements. Clin. Chem.
2007;53:784-787.
15. Dalla Man C, Caumo A, Cobelli C. The oral glucose minimal
model: estimation of insulin sensitivity from a meal test. IEEE
Trans Biomed Eng. 2002;49:419-429.
16. Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C.
Oral glucose tolerance test minimal model indexes of beta-cell
function and insulin sensitivity. Diabetes. 2001;50:150-158.
17. Cobelli C, Toffolo GM, Dalla Man C, et al. Assessment of beta-
cell function in humans, simultaneously with insulin sensitivity
and hepatic extraction, from intravenous and oral glucose tests.
Am J Physiol Endocrinol Metab. 2007;293:E1-E15.
18. CaumoA, BergmanRN, Cobelli C. Insulin sensitivity frommeal
tolerance tests in normal subjects: a minimal model index. J Clin
Endocrinol Metab. 2000;85:4396-4402.
19. Dalla Man C, Caumo A, Basu R, Rizza R, Toffolo G, Cobelli
C. Minimal model estimation of glucose absorption and insulin
sensitivity from oral test: validation with a tracer method. Am J
Physiol Endocrinol Metab. 2004;287:E637-E643.
20. DallaManC, CampioniM, PolonskyKS, et al. Two-hour seven-
sample oral glucose tolerance test and meal protocol: minimal
model assessment of beta-cell responsivity and insulin sensitivity
in nondiabetic individuals. Diabetes. 2005;54:3265-3273.
21. Zhang X, Wang X, Vernikovskaya DI, et al. Quantitative
determination of metformin, glyburide and its metabolites in
plasma and urine of pregnant patients by LC-MS/MS. Biomed
Chromatogr. 2015;29:560-569.
22. R Core Team. R: A Language and Environment for Statistical
Computing. Vienna, Austria: R Foundation for Statistical Com-
puting; 2018.
23. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New
York: Springer-Verlag; 2016.
24. Yerby MS, Friel PN, McCormick K et al. Pharmacokinetics
of anticonvulsants in pregnancy: alterations in plasma protein
binding. Epilepsy Res. 1990;5(3):223-228.
25. Zajdenverg L, Negrato CA. Gestational diabetes mellitus and
type 2 diabetes: same disease in a different moment of life?
Maybe not. Arch Endocrinol Metab. 2017;61:208-210.
26. XiangAH, PetersRK,Kjos SL, et al. Pharmacological treatment
of insulin resistance at two different stages in the evolution of
type 2 diabetes: impact on glucose tolerance and β-cell function.
J Clin Endocrinol Metab. 2004;89:2846-2851.
27. BellamyL,Casas JP,HingoraniAD,WilliamsD.Type 2 diabetes
mellitus after gestational diabetes: a systematic review and meta-
analysis. Lancet. 2009;373:1773-1779.
28. Wiernsperger NF, Bailey CJ. Antihyperglycaemic effect of met-
formin: therapeutic and cellular mechanisms.Drugs. 1999;58:31-
82.
29. Scarpello JH, Howlett HC.Metformin therapy and clinical uses.
Diabetes Vasc Dis Res. 2008;5:157-167.
30. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplifica-
tion of the late phase insulin response to glucose by GIP in obese
type II diabetic patients. Diabetologia. 2002;45:1111-1119.
31. Tran KL, Park YI, Pandya S, et al. Overview of glucagon-like
peptide-1 receptor agonists or the treatment of patients with type
2 diabetes. Am Health Drug Benefits. 2017;10:178-188.
32. Williams-Herman D, Xu L, Teng R, et al. Effect of initial
combination therapy with sitagliptin and metformin on β-cell
function in patients with type 2 diabetes. Diabetes Obes Metab.
2012;14:67-76.
